153 related articles for article (PubMed ID: 38875109)
21. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
Arachchillage DR; Laffan M
Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
[TBL] [Abstract][Full Text] [Related]
22. Inherited polygenic effects on common hematological traits influence clonal selection on JAK2
Guo J; Walter K; Quiros PM; Gu M; Baxter EJ; Danesh J; Di Angelantonio E; Roberts D; Guglielmelli P; Harrison CN; Godfrey AL; Green AR; Vassiliou GS; Vuckovic D; Nangalia J; Soranzo N
Nat Genet; 2024 Feb; 56(2):273-280. PubMed ID: 38233595
[TBL] [Abstract][Full Text] [Related]
23. Germline genetic factors in the pathogenesis of myeloproliferative neoplasms.
Bellanné-Chantelot C; Rabadan Moraes G; Schmaltz-Panneau B; Marty C; Vainchenker W; Plo I
Blood Rev; 2020 Jul; 42():100710. PubMed ID: 32532454
[TBL] [Abstract][Full Text] [Related]
24. Mathematical modelling of the hematopoietic stem cell-niche system: Clonal dominance based on stem cell fitness.
Pedersen RK; Andersen M; Stiehl T; Ottesen JT
J Theor Biol; 2021 Jun; 518():110620. PubMed ID: 33587928
[TBL] [Abstract][Full Text] [Related]
25. Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm.
Fleischman AG
Mediators Inflamm; 2015; 2015():606819. PubMed ID: 26538830
[TBL] [Abstract][Full Text] [Related]
26. Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms.
Bermes M; Rodriguez MJ; de Toledo MAS; Ernst S; Müller-Newen G; Brümmendorf TH; Chatain N; Koschmieder S; Baumeister J
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139386
[TBL] [Abstract][Full Text] [Related]
27. A progenitor cell origin of myeloid malignancies.
Haeno H; Levine RL; Gilliland DG; Michor F
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16616-21. PubMed ID: 19805346
[TBL] [Abstract][Full Text] [Related]
28. Thrombosis and hemorrhage in myeloproliferative neoplasms: The platelet perspective.
Feng Y; Zhang Y; Shi J
Platelets; 2022 Oct; 33(7):955-963. PubMed ID: 35081860
[TBL] [Abstract][Full Text] [Related]
29. Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms.
Forsyth CJ; Chan WH; Grigg AP; Cook NC; Lane SW; Burbury KL; Perkins AC; Ross DM
Intern Med J; 2019 Aug; 49(8):948-954. PubMed ID: 30411442
[TBL] [Abstract][Full Text] [Related]
30. Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu/BCAM.
Novitzky-Basso I; Spring F; Anstee D; Tripathi D; Chen F
Int J Lab Hematol; 2018 Aug; 40(4):473-477. PubMed ID: 29756283
[TBL] [Abstract][Full Text] [Related]
31. Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies.
Brune MM; Rau A; Overkamp M; Flaadt T; Bonzheim I; Schürch CM; Federmann B; Dirnhofer S; Fend F; Tzankov A
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830756
[TBL] [Abstract][Full Text] [Related]
32. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway.
Lu M; Zhang W; Li Y; Berenzon D; Wang X; Wang J; Mascarenhas J; Xu M; Hoffman R
Exp Hematol; 2010 Jun; 38(6):472-80. PubMed ID: 20303384
[TBL] [Abstract][Full Text] [Related]
33. Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms.
Herbreteau L; Papageorgiou L; Le Clech L; Garcia G; James C; Pan-Petesch B; Couturaud F; Gerotziafas G; Lippert E; Ianotto JC
Thromb Res; 2022 Aug; 216():25-34. PubMed ID: 35689962
[TBL] [Abstract][Full Text] [Related]
34. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
35. Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved.
Bhuria V; Baldauf CK; Schraven B; Fischer T
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328626
[TBL] [Abstract][Full Text] [Related]
36. Transcriptional configurations of myeloproliferative neoplasms.
Schischlik F
Int Rev Cell Mol Biol; 2022; 366():25-39. PubMed ID: 35153005
[TBL] [Abstract][Full Text] [Related]
37. Novel Detection of CALR-Mutated Cells in Myeloproliferative Neoplasm-Related Glomerulopathy With Interstitial Extramedullary Hematopoiesis: A Case Report.
Maruyama K; Nakagawa N; Suzuki A; Kabara M; Matsuki M; Shindo M; Iwasaki S; Ogawa Y; Hasebe N
Am J Kidney Dis; 2019 Dec; 74(6):844-848. PubMed ID: 31377025
[TBL] [Abstract][Full Text] [Related]
38. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
[TBL] [Abstract][Full Text] [Related]
39. Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
Patel PR; Senyuk V; Rodriguez NS; Oh AL; Bonetti E; Mahmud D; Barosi G; Mahmud N; Rondelli D
Biol Blood Marrow Transplant; 2019 May; 25(5):855-860. PubMed ID: 30615982
[TBL] [Abstract][Full Text] [Related]
40. Impact of mutations on pregnancy outcome in patients with myeloproliferative neoplasms.
Maze D; Arusi I; Gupta V; Atenafu EG; Malinowski AK; Shehata N
EJHaem; 2023 Feb; 4(1):241-245. PubMed ID: 36819152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
